Comments
Claris Lifesciences Limited (Claris) has received the Supplemental Abbreviated New Drug Application (ANDA) approval for Fluconazole Injection in the US market, the company informed in a statement on Tuesday.
Claris is currently marketing Fluconazole in 2 mg/ml formulation packed in 100 ml and 200 ml PVC Bags and now with the approval of supplemental ANDA, Claris is the only company to be able to sell Fluconazole in 50 ml variant in the US, the statement said.
By launching this variant Claris will be addressing the need of the medical fraternity.
Claris has 13 ANDAs approved in its name across 8 molecules. The Company has a under registration pipeline of 25 ANDAs across 22 molecules having an estimated addressable market size of USD 2.2 Bn.
Claris shares ended 1.06 per cent or Rs 2.90 at Rs 277.30 on the BSE on Tuesday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.